Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
J Infect Dis
; 184(10): 1331-5, 2001 Nov 15.
Article
in En
| MEDLINE
| ID: mdl-11679925
ABSTRACT
Infants born to human immunodeficiency virus type 1 (HIV-1)-infected mothers were immunized at birth and at ages 4, 12, and 20 weeks with low-, medium-, or high-dose recombinant gp120 vaccine with MF59 adjuvant (HIV-1(SF-2); n=52) or with MF59 alone as a placebo (n=9). An accelerated schedule (birth and ages 2, 8, and 20 weeks) was used for an additional 10 infants receiving the defined optimal dose and for 3 infants receiving placebo. At 24 weeks, anti-gp120 ELISA titers were greater for vaccine-immunized than for placebo-immunized infants on both schedules, and 87% of vaccinees had a vaccine-induced antibody response. At 12 weeks, antibody titers of infants on the accelerated vaccine schedule exceeded those of infants receiving placebo (4949 vs. 551; P=.01), and 63% of the vaccinees met the response criteria. Thus, an accelerated schedule of gp120 vaccinations generated an antibody response to HIV-1 envelope distinct from transplacental maternal antibody by age 12 weeks. These results provide support for further studies of vaccine strategies to prevent mother-to-infant HIV-1 transmission.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Envelope Protein gp120
/
HIV Infections
/
HIV-1
/
Vaccination
/
AIDS Vaccines
/
Antibodies, Viral
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Infant
/
Male
/
Newborn
/
Pregnancy
Language:
En
Journal:
J Infect Dis
Year:
2001
Document type:
Article
Affiliation country:
Estados Unidos